In 2017, the Union for International Cancer Control (UICC) used immunohistochemical (IHC) marker p16 as a surrogate for HPV infection to separate oropharyngeal cancer (OPC) into p16-positive and p16-negative OPC due to differences in molecular structure, tumor characteristics and treatment results.